TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 0
Operating Income -61.4M
Net Income -55.2M
EPS (Diluted) $-1.58

Balance Sheet Metrics

Total Assets 709.3M
Total Liabilities 48.9M
Shareholders Equity 660.4M
Debt to Equity 0.07

Cash Flow Metrics

Operating Cash Flow -45.8M
Free Cash Flow -48.0M

Revenue & Profitability Trend

Disc Medicine Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i96.7M69.3M33.4M25.2M28.2M
Selling, General & Administrative i33.0M21.9M14.0M5.8M5.9M
Other Operating Expenses i-----
Total Operating Expenses i129.7M91.1M47.5M30.9M34.0M
Operating Income i-129.7M-91.1M-47.5M-30.9M-34.0M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i21.3M14.8M709.0K14.0K37.0K
Interest Expense i572.0K--2.2M6.8M
Other Non-Operating Income-2.0K-2.0K-61.0K-5.0M-8.0K
Pre-tax Income i-109.0M-76.3M-46.8M-36.0M-40.8M
Income Tax i355.0K99.0K0--
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-109.4M-76.4M-46.8M-36.0M-40.8M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-108.3M-91.0M-47.3M-25.9M-33.7M
EPS (Basic) i$-3.96$-3.42$-45.05$-44.90$-9.01
EPS (Diluted) i$-3.96$-3.42$-45.05$-44.90$-9.01
Basic Shares Outstanding i276060222231587710394908014674530199
Diluted Shares Outstanding i276060222231587710394908014674530199

Income Statement Trend

Disc Medicine Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i192.4M360.4M194.6M88.0M4.5M
Short-term Investments i297.4M----
Accounts Receivable i-----
Inventory i-----
Other Current Assets3.7M5.3M3.9M2.4M-
Total Current Assets i493.6M365.7M198.5M90.5M5.1M
Non-Current Assets
Property, Plant & Equipment i1.6M1.9M1.4M1.6M808.0K
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets838.0K234.0K116.0K180.0K3.0M
Total Non-Current Assets i3.2M2.3M1.7M1.9M3.3M
Total Assets i496.8M368.0M200.2M92.4M8.3M
Liabilities
Current Liabilities
Accounts Payable i7.9M12.6M16.2M2.6M2.4M
Short-term Debt i130.0K665.0K307.0K319.0K16.7M
Current Portion of Long-term Debt-----
Other Current Liabilities---6.4M-
Total Current Liabilities i23.3M21.4M22.6M13.4M24.9M
Non-Current Liabilities
Long-term Debt i29.9M1.4M1.0M1.3M5.0M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities---358.0K277.0K
Total Non-Current Liabilities i29.9M1.4M1.0M143.2M5.3M
Total Liabilities i53.2M22.9M23.6M156.6M30.2M
Equity
Common Stock i3.0K2.0K2.0K02.0K
Retained Earnings i-298.0M-188.6M-112.2M-65.4M-112.8M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i443.6M345.1M176.6M-64.2M-21.9M
Key Metrics
Total Debt i30.0M2.1M1.3M1.7M21.6M
Working Capital i470.3M344.2M175.9M77.1M-19.8M

Balance Sheet Composition

Disc Medicine Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-109.4M-76.4M-46.8M-36.0M-40.8M
Depreciation & Amortization i156.0K100.0K89.0K32.0K322.0K
Stock-Based Compensation i16.8M5.5M2.1M507.0K983.0K
Working Capital Changes i-5.2M-3.8M271.0K2.5M-3.7M
Operating Cash Flow i-97.0M-74.3M-44.2M-31.4M-36.8M
Investing Activities
Capital Expenditures i-505.0K-89.0K-151.0K-68.0K-22.0K
Acquisitions i-----
Investment Purchases i-386.6M----
Investment Sales i94.8M----
Investing Cash Flow i-292.3M-89.0K-151.0K-68.0K-22.0K
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i29.0M--014.0M
Debt Repayment i----4.6M0
Financing Cash Flow i214.9M199.1M148.8M281.2M34.1M
Free Cash Flow i-94.4M-73.6M-42.4M-27.6M-32.7M
Net Change in Cash i-174.5M124.7M104.4M249.7M-2.7M

Cash Flow Trend

Disc Medicine Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 4.99
Forward P/E -11.07
Price to Book 3.29
PEG Ratio 0.09

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -26.36%
Return on Assets -17.95%

Financial Health

Current Ratio 32.11
Debt to Equity 5.04
Beta 2.50

Per Share Data

EPS (TTM) $-4.46
Book Value per Share $17.70
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
iron2.0B4.993.29-26.36%0.00%5.04
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
BridgeBio Pharma 9.6B-17.12-5.2836.76%98.25%-1.04
Madrigal 8.5B-17.6712.12-36.30%-54.68%17.81
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.